highlights of the 10-Q:
The Company has incurred significant losses from operations, resulting in an accumulated deficit of $49,846,000. The Company expects such losses to continue
no assurance can be given that Dr. Schewe will continue to fund the Company or that contracts will be obtained in the future, or if they are obtained, that they will be profitable. Accordingly, there continues to be substantial doubt as to the Company’s ability to continue as a going concern
One or more fully-executed, third party sales contracts for the sale of Giant King Grass shall have been entered into during the Initial Term, pursuant to which VIASPACE is to be paid an aggregate amount of at least $200,000 within that 24 consecutive monthly period; and two or more, third party growing locations of at least 10 hectares in total shall have been obtained and planted during the Initial Term. The Company expects to meet the milestones by September 30, 2014 and renew the license for an additional two year term. The Company has entered into various collaborative agreements with entities for the joint operation of test plots that the Company believes will help to satisfy these milestones. However, there can be no assurance that the Company will meet the milestones prior to the renewal date
For the six months ended June 30, 2014, the Company had a loss from operations of $332,000 compared with a loss from operations of $285,000 for the six months ended June 30, 2013, an increase of $47,000
The Company has incurred significant losses from operations, resulting in an accumulated deficit of $49,846,000 at June 30, 2014
We can give no assurance that we will achieve or sustain profitability
We anticipate that the issuance of newly-issued shares to maintain our business will likely be very dilutive
News 
Market Data 
Discover 
